Cite
Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.
MLA
Remuzgo-Martínez, Sara, et al. “Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.” Frontiers in Immunology, vol. 13, July 2022, p. 894171. EBSCOhost, https://doi.org/10.3389/fimmu.2022.894171.
APA
Remuzgo-Martínez, S., Rueda-Gotor, J., Pulito-Cueto, V., López-Mejías, R., Corrales, A., Lera-Gómez, L., Pérez-Fernández, R., Portilla, V., González-Mazón, Í., Blanco, R., Expósito, R., Mata, C., Llorca, J., Hernández-Hernández, V., Rodríguez-Lozano, C., Barbarroja, N., Ortega-Castro, R., Vicente, E., Fernández-Carballido, C., … Genre, F. (2022). Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Frontiers in Immunology, 13, 894171. https://doi.org/10.3389/fimmu.2022.894171
Chicago
Remuzgo-Martínez, Sara, Javier Rueda-Gotor, Verónica Pulito-Cueto, Raquel López-Mejías, Alfonso Corrales, Leticia Lera-Gómez, Raquel Pérez-Fernández, et al. 2022. “Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.” Frontiers in Immunology 13 (July): 894171. doi:10.3389/fimmu.2022.894171.